Jason Meyenburg
Chief Executive Officer bij Gemini Therapeutics Sub, Inc.
Profiel
Jason Meyenburg currently works at Gemini Therapeutics Sub, Inc., as Chief Executive Officer & Director from 2019.
Mr. Meyenburg also formerly worked at Gemini Therapeutics, Inc., as President, Chief Executive Officer & Director, Alexion Pharmaceuticals, Inc., as Senior Vice President-Commercial Operations from 2003 to 2016, Sucampo Pharmaceuticals, Inc., as Chief Commercial Officer from 2017 to 2018, Alexion Pharma GmbH, as Vice President-Commercial Operations from 2010 to 2014, Vtesse, Inc., as Chief Commercial Officer from 2016 to 2017, and Orchard Therapeutics Plc, as Chief Commercial Officer from 2018 to 2019.
Mr. Meyenburg received his undergraduate degree from the University of Maryland and Masters Business Admin degree from The Fuqua School of Business.
Actieve functies van Jason Meyenburg
Bedrijven | Functie | Begin |
---|---|---|
Gemini Therapeutics Sub, Inc.
Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | Chief Executive Officer | 13-09-2019 |
Eerdere bekende functies van Jason Meyenburg
Bedrijven | Functie | Einde |
---|---|---|
GEMI THER | Chief Executive Officer | 28-02-2022 |
ORCHARD THERAPEUTICS PLC | Corporate Officer/Principal | 13-09-2019 |
SUCAMPO PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-03-2018 |
Vtesse, Inc.
Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | 01-04-2017 |
ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-02-2016 |
Opleiding van Jason Meyenburg
University of Maryland | Undergraduate Degree |
The Fuqua School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 7 |
---|---|
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products. The company was founded by Ryuji Ueno and Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD. | Health Technology |
Alexion Pharma GmbH | |
Vtesse, Inc.
Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Health Technology |
Gemini Therapeutics Sub, Inc.
Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | Health Technology |
Orchard Therapeutics Plc
Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
Gemini Therapeutics, Inc.
Gemini Therapeutics, Inc. BiotechnologyHealth Technology Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA. | Health Technology |